Filing Details
- Accession Number:
- 0001127602-24-028397
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-03 14:43:20
- Reporting Period:
- 2024-11-29
- Accepted Time:
- 2024-12-03 14:43:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc. | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1310204 | D Andrew Dickinson | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-11-29 | 18,630 | $73.77 | 157,549 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-11-29 | 26,170 | $57.92 | 183,719 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-11-29 | 33,660 | $68.75 | 217,379 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-11-29 | 60,885 | $71.91 | 278,264 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-11-29 | 43,340 | $72.70 | 321,604 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-11-29 | 65,960 | $72.70 | 387,564 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-11-29 | 120,715 | $92.77 | 266,849 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-11-29 | 127,930 | $92.76 | 138,919 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2024-11-29 | 26,170 | $0.00 | 26,170 | $57.92 |
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2024-11-29 | 18,630 | $0.00 | 18,630 | $73.77 |
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2024-11-29 | 33,660 | $0.00 | 33,660 | $68.75 |
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2024-11-29 | 60,885 | $0.00 | 60,885 | $71.91 |
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2024-11-29 | 43,340 | $0.00 | 43,340 | $72.70 |
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2024-11-29 | 65,960 | $0.00 | 65,960 | $72.70 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
130,860 | 2032-03-10 | No | 4 | M | Direct | |
0 | 2027-11-10 | No | 4 | M | Direct | |
0 | 2029-02-06 | No | 4 | M | Direct | |
0 | 2028-06-10 | No | 4 | M | Direct | |
0 | 2027-08-10 | No | 4 | M | Direct | |
0 | 2026-12-10 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
- Sales prices reported for the transactions reported here range from $92.36 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sales prices reported for the transactions reported here range from $92.33 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested.